🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Taizhou Mabtech Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Taizhou Mabtech Pharmaceutical as lead sponsor. Synced 26 Sep 2026
7Current trials
2Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Taizhou Mabtech Pharmaceutical is the lead sponsor of 7 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Enlituo, Erbitux and Omalizumab. The most-studied condition is Healthy Adult Male.

ClinicalTrials.gov trials by status

  • Recruiting229%
  • Not yet open229%
  • Active, closed343%

Trials by phase

  • Phase 1343%
  • Phase 3229%
  • Phase 2/3114%
  • Phase 4114%
01

Clinical trials sponsored by Taizhou Mabtech Pharmaceutical

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
NCT06933069 · ClinicalTrials.gov ↗ · Solid Malignancies
Phase 1 Recruiting 2025-06 China
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NCT05906576 · ClinicalTrials.gov ↗ · Crohn Disease
Phase 4 Recruiting 2023-09 China
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
NCT07791745 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Drug: Enlituo
Phase 2/3 Not yet open 2026-08 China
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
NCT07595276 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 3 Not yet open 2026-06 China
Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers
NCT07246291 · ClinicalTrials.gov ↗ · Healthy Adult Male
Phase 1 Active, closed 2025-11 China
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
NCT06365879 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria
Phase 3 Active, closed 2024-06 China
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
NCT07254325 · ClinicalTrials.gov ↗ · Psoriasis
Phase 1 Active, closed 2025-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Taizhou Mabtech Pharmaceutical trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Taizhou Mabtech Pharmaceutical trials

7 conditions
Healthy Adult Male1Solid Malignancies1Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)1Crohn Disease1Colorectal Cancer1Chronic Spontaneous Urticaria1Psoriasis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China72

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Healthy Adult Male

SponsorTrials
University of Electronic Science and Technology of China2

Sponsors with the most current trials registered for this condition.

06

Questions about Taizhou Mabtech Pharmaceutical trials

How many clinical trials does Taizhou Mabtech Pharmaceutical sponsor?

Taizhou Mabtech Pharmaceutical is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Taizhou Mabtech Pharmaceutical trials recruiting?

Yes. 2 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Taizhou Mabtech Pharmaceutical testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Enlituo (2), Erbitux (1), Omalizumab (1) and Secukinumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.